Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Platelet transfusions are crucial for hemostasis in acute coronary syndrome (ACS) patients.
• Thienopyridine antiplatelet agents, like prasugrel, can impair the efficacy of platelet transfusions due to their active metabolites.
• Understanding the duration of prasugrel's active metabolite inhibition is critical for optimizing transfusion strategies.

Purpose of the Study:

• To determine the earliest time point after a prasugrel loading dose when added platelets are no longer affected by the drug's active metabolite.
• To provide data that can inform transfusion timing in ACS patients treated with prasugrel.

Main Methods:

• Healthy subjects (n=25) on aspirin received a prasugrel loading dose.
• Platelet reactivity was assessed using Maximum Platelet Aggregation (MPA) and VerifyNow® P2Y12 assays.
• Ex-vivo addition of platelets from untreated donors at varying concentrations (40%, 60%, 80%) was performed at 2, 6, 12, and 24 hours post-prasugrel dose.

Main Results:

• Supplemented platelets demonstrated increased reactivity in a concentration-dependent manner across all time points.
• Platelet reactivity significantly increased between 2 and 6 hours post-prasugrel administration.
• Platelet reactivity remained stable between 6 and 12 hours, indicating the dissipation of the active metabolite's inhibitory effect.

Conclusions:

• The earliest time that supplemented platelets were not inhibited by prasugrel's active metabolite was observed at 6 hours post-loading dose.
• These findings suggest that platelet transfusions administered 6 hours or later after a prasugrel loading dose may be more effective in ACS patients.
• This has significant clinical implications for managing ACS patients requiring transfusions during critical periods, such as surgery.